Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Alpine Immune Sciences Inc (ALPN)

Alpine Immune Sciences Inc (ALPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 261,124
  • Shares Outstanding, K 30,328
  • Annual Sales, $ 23,440 K
  • Annual Income, $ -50,330 K
  • 60-Month Beta 1.71
  • Price/Sales 11.01
  • Price/Cash Flow N/A
  • Price/Book 2.24
Trade ALPN with:

Options Overview Details

View History
  • Implied Volatility 129.57% ( -11.89%)
  • Historical Volatility 44.81%
  • IV Percentile 74%
  • IV Rank 48.54%
  • IV High 216.12% on 03/07/22
  • IV Low 47.91% on 09/20/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 2
  • Put/Call OI Ratio 0.38
  • Today's Open Interest 183
  • Open Int (30-Day) 187

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.39
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.58
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +15.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.22 +19.25%
on 06/30/22
9.65 -10.73%
on 06/07/22
-0.24 (-2.71%)
since 06/01/22
3-Month
6.40 +34.53%
on 05/12/22
9.95 -13.47%
on 05/03/22
-0.36 (-4.01%)
since 04/01/22
52-Week
6.00 +43.50%
on 02/22/22
14.40 -40.21%
on 12/31/21
-0.19 (-2.16%)
since 07/01/21

Most Recent Stories

More News
Revolution Medicines, Inc. (RVMD) Surges 5.6%: Is This an Indication of Further Gains?

Revolution Medicines, Inc. (RVMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in...

RVMD : 20.89 (+7.18%)
ALPN : 8.61 (+1.18%)
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.61 (+1.18%)
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.61 (+1.18%)
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.61 (+1.18%)
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.61 (+1.18%)
Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -47.06% and 2.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

ALPN : 8.61 (+1.18%)
COO : 318.51 (+1.72%)
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today provided...

ALPN : 8.61 (+1.18%)
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OCUL : 4.09 (+1.74%)
ALPN : 8.61 (+1.18%)
Endo International (ENDP) Surpasses Q1 Earnings and Revenue Estimates

Endo (ENDP) delivered earnings and revenue surprises of 50% and 1.73%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ENDP : 0.5701 (+22.42%)
ALPN : 8.61 (+1.18%)
Alpine Immune Sciences Announces Participation in May Investor Conferences

Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced...

ALPN : 8.61 (+1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based...

See More

Key Turning Points

3rd Resistance Point 9.25
2nd Resistance Point 9.02
1st Resistance Point 8.82
Last Price 8.61
1st Support Level 8.39
2nd Support Level 8.16
3rd Support Level 7.96

See More

52-Week High 14.40
Fibonacci 61.8% 11.19
Fibonacci 50% 10.20
Fibonacci 38.2% 9.21
Last Price 8.61
52-Week Low 6.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar